This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Leckband, S. G. Articles by Ellingrod, V. L. Search for Related Content Social Bookmarking                   What's this?

Pharmacogenomics in Psychiatry

Veterans Affairs San Diego Healthcare System, San Diego, California

Jeffrey R. Bishop, PharmD, MS, BCPP

University of Illinois at Chicago College of Pharmacy, Chicago, Illinois

Vicki L. Ellingrod, PharmD, BCPP

University of Michigan College of Pharmacy, Department of Clinical Sciences and School of Medicine, vellingr{at}umich.edu, Department of Psychiatry, 428 Church Street, Ann Arbor, Michigan

Pharmacogenomics may provide us with the means to expedite treatment for patients with various psychiatric disorders. Treatment is presently hampered by individual variation in medication response that often results in an extended trial-and-error process of treatment until the optimal medication is found. This can extend the time until treatment optimization to months or years. Much of this variation may be genetically based. This review discusses current pharmacogenomics research in mood disorders and in schizophrenia. Although the field is in an early stage, results already suggest that DNA tests will one day be of clinical value in the optimal selection of medications for mood and thought disorders.

Key Words: Pharmacogenetics • pharmacogenomics • mood disorders • schizophrenia • antidepressant • antipsychotic.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?